Skip to main content

Familial Adenomatous Polyposis

1
Pipeline Programs
3
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biodexa Pharmaceuticals
1 program
1
Encapsulated RapamycinPhase 21 trial
Active Trials
NCT04230499Active Not Recruiting30Est. Mar 2025
General Oncology
General OncologyMA - Brookline
2 programs
Personalized surveillance and intervention protocolN/A1 trial
Personalized surveillance and intervention protocolN/A1 trial
Active Trials
NCT04677998Recruiting1,000Est. Nov 2027
NCT04678011Recruiting1,000Est. Nov 2026
Recursion Pharmaceuticals
Recursion PharmaceuticalsSALT LAKE CITY, UT
1 program
REC-4881PHASE_1_21 trial
Active Trials
NCT05552755Recruiting67Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Biodexa PharmaceuticalsEncapsulated Rapamycin
Recursion PharmaceuticalsREC-4881
General OncologyPersonalized surveillance and intervention protocol
General OncologyPersonalized surveillance and intervention protocol

Clinical Trials (4)

Total enrollment: 2,097 patients across 4 trials

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Start: Jan 2021Est. completion: Mar 202530 patients
Phase 2Active Not Recruiting

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

Start: Jul 2023Est. completion: Sep 202767 patients
Phase 1/2Recruiting
NCT04678011General OncologyPersonalized surveillance and intervention protocol

A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy

Start: Nov 2021Est. completion: Nov 20261,000 patients
N/ARecruiting
NCT04677998General OncologyPersonalized surveillance and intervention protocol

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

Start: Nov 2020Est. completion: Nov 20271,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 2,097 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.